Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorSecond Hospital of Shanxi Medical University
About this trial
This study is a single arm, open, multicenter phase II study. The main purpose of this study was to evaluate preliminary efficacy and safety of Tislelizumab combined with thoracic radiotherapy as first line therapy for Extensive stage small cell lung cancer.
Eligibility criteria
Qualifiers
Patients aged between 18 to 80 years old (inclusive of 18th and 80th birthdays), male or female, at the time of signing the informed consent form;
Confirmed small cell lung cancer of extensive stage by histology or cytology;
At least one measurable lesion by imaging studies (according to RECIST 1.1) with a long diameter of ≥10 mm as examined by spiral CT or MRI;
Within 3 days prior to treatment, an ECOG score of 0 to 1;
Disqualifiers
Concurrent severe respiratory diseases: such as pulmonary fibrosis;
Presence of psychiatric disorders, hematologic diseases, autoimmune diseases, and severe primary diseases of the heart, brain, liver, or kidneys;
Uncontrolled active infections;
Known or suspected allergies to the study medication and its excipients;
Trial design
Treatments tested in this trial
- Tislelizumab
- Etoposide
- Carboplatin or Cisplatin
- Thoracic radiotherapy
Treatment groups
40 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov